新出现的冠状病毒感染概述,COVID-19:疫苗开发和治疗的现状

M. Rana, Maruf Hasan, Md. Eshak Enan, F. Zohora, A. Azam
{"title":"新出现的冠状病毒感染概述,COVID-19:疫苗开发和治疗的现状","authors":"M. Rana, Maruf Hasan, Md. Eshak Enan, F. Zohora, A. Azam","doi":"10.4236/PP.2021.121003","DOIUrl":null,"url":null,"abstract":"Coronavirus \ninfectious disease 2019 (COVID-19) first reported in Wuhan, China, causes serious \nrespiratory illnesses such as lung failure and pneumonia. Severe Acute Respiratory \nSyndrome Coronavirus 2 (SARS-CoV-2) the pathogenic agent of COVID-19 has been confirmed as a novel coronavirus. \nWHO announced COVID-19 a global pandemic and now the whole world is eagerly waiting for vaccines and therapeutic treatment to get \nrid of this unstoppable coronavirus. As COVID-19 infection, a global threat creates \nunwanted human casualties and serious economic loss. To stop the ongoing uncontrolled \nsituation researchers are racing to develop prevention and treatment strategies. \nVaccines of different countries are in clinical and preclinical trials and the repurposed-drugs \nare providing to find out a positive result against COVID-19. The report is an analysis of published information \nfocusing on treatment options including vaccination, drug-therapy, cytokines, therapeutic \nantibodies. Most of the vaccine’s development strategies and drugs target the surface structural spike glycoprotein \nor S-protein, the major inducer of pathogenic responses. Here, it is reviewed the \nfeatures of SARS-CoV-2 and the global current status of therapeutic, and vaccine development for the prevention \nand effective treatment of COVID-19.","PeriodicalId":20031,"journal":{"name":"Pharmacology & Pharmacy","volume":"28 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Overview of an Emerging Coronavirus Infection, COVID-19: Current Status of Vaccine Development and Therapeutics\",\"authors\":\"M. Rana, Maruf Hasan, Md. Eshak Enan, F. Zohora, A. Azam\",\"doi\":\"10.4236/PP.2021.121003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Coronavirus \\ninfectious disease 2019 (COVID-19) first reported in Wuhan, China, causes serious \\nrespiratory illnesses such as lung failure and pneumonia. Severe Acute Respiratory \\nSyndrome Coronavirus 2 (SARS-CoV-2) the pathogenic agent of COVID-19 has been confirmed as a novel coronavirus. \\nWHO announced COVID-19 a global pandemic and now the whole world is eagerly waiting for vaccines and therapeutic treatment to get \\nrid of this unstoppable coronavirus. As COVID-19 infection, a global threat creates \\nunwanted human casualties and serious economic loss. To stop the ongoing uncontrolled \\nsituation researchers are racing to develop prevention and treatment strategies. \\nVaccines of different countries are in clinical and preclinical trials and the repurposed-drugs \\nare providing to find out a positive result against COVID-19. The report is an analysis of published information \\nfocusing on treatment options including vaccination, drug-therapy, cytokines, therapeutic \\nantibodies. Most of the vaccine’s development strategies and drugs target the surface structural spike glycoprotein \\nor S-protein, the major inducer of pathogenic responses. Here, it is reviewed the \\nfeatures of SARS-CoV-2 and the global current status of therapeutic, and vaccine development for the prevention \\nand effective treatment of COVID-19.\",\"PeriodicalId\":20031,\"journal\":{\"name\":\"Pharmacology & Pharmacy\",\"volume\":\"28 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacology & Pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4236/PP.2021.121003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology & Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4236/PP.2021.121003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

2019冠状病毒传染病(COVID-19)首次在中国武汉报告,可导致肺衰竭和肺炎等严重呼吸系统疾病。严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)是一种新型冠状病毒。世卫组织宣布COVID-19为全球大流行,现在全世界都在急切地等待疫苗和治疗方法,以摆脱这种不可阻挡的冠状病毒。COVID-19感染是一种全球性威胁,造成不必要的人员伤亡和严重的经济损失。为了阻止持续的不受控制的情况,研究人员正在竞相制定预防和治疗策略。各国的疫苗正在进行临床和临床前试验,并正在提供重新使用的药物,以确定对新冠病毒的阳性结果。该报告是对已发表信息的分析,重点是治疗方案,包括疫苗接种、药物治疗、细胞因子、治疗性抗体。大多数疫苗的开发策略和药物靶向表面结构刺突糖蛋白或s蛋白,这是致病反应的主要诱导剂。本文综述了SARS-CoV-2的特点、全球治疗现状以及预防和有效治疗COVID-19的疫苗开发情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Overview of an Emerging Coronavirus Infection, COVID-19: Current Status of Vaccine Development and Therapeutics
Coronavirus infectious disease 2019 (COVID-19) first reported in Wuhan, China, causes serious respiratory illnesses such as lung failure and pneumonia. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) the pathogenic agent of COVID-19 has been confirmed as a novel coronavirus. WHO announced COVID-19 a global pandemic and now the whole world is eagerly waiting for vaccines and therapeutic treatment to get rid of this unstoppable coronavirus. As COVID-19 infection, a global threat creates unwanted human casualties and serious economic loss. To stop the ongoing uncontrolled situation researchers are racing to develop prevention and treatment strategies. Vaccines of different countries are in clinical and preclinical trials and the repurposed-drugs are providing to find out a positive result against COVID-19. The report is an analysis of published information focusing on treatment options including vaccination, drug-therapy, cytokines, therapeutic antibodies. Most of the vaccine’s development strategies and drugs target the surface structural spike glycoprotein or S-protein, the major inducer of pathogenic responses. Here, it is reviewed the features of SARS-CoV-2 and the global current status of therapeutic, and vaccine development for the prevention and effective treatment of COVID-19.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Quantitative determination of total flavonoids in Glycyrrhiza Glabra L. herbs New role of extemporaneous manufacturing in regulating drug products access onto the market “Off-label” drugs: legal problems and socio-economic aspects of application practice Analysis of cytokine response characteristics and immunopathogenetic effects of double-stranded sodium salt RNA-based drug for postexposure prophylaxis against novel coronavirus infection: double-blind, placebo-controlled trial Development of composition and technology for obtaining antimicrobial composition based on mono- and sesquiterpenoids
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1